AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Marilyn Much
Officials at Immucor aim to automate the job of analyzing blood at as many hospitals and labs as they can. The key is to keep churning out new products.
Immucor makes automated systems and reagents to test blood prior to transfusion.
Two years ago the company launched in Europe its second-generation, fully automated blood typing and antibody screening instrument called Galileo. It's a high-volume machine designed for use at larger hospitals and clinical labs.
In April, Immucor got Food and Drug Administration approval to sell the product in the U.S. In July, it became licensed to sell it in Japan and Canada.
The company's next major product is due around May 2006, when it's expected to launch a third-generation, fully automated blood typing and screening instrument. Dubbed the G-3, this product is aimed at small to midsize hospitals.
That's a big target market. Immucor Chief Financial Officer Steven Ramsey estimates that 5,000 to 6,000 hospitals worldwide qualify.